MENTOR heralds a new era of therapy for membranous nephropathy

Nature Reviews Nephrology, Published online: 23 August 2019; doi:10.1038/s41581-019-0200-1The MENTOR trial reported that rituximab is superior to ciclosporin for remission of nephrotic syndrome in patients with membranous nephropathy. Rituximab is better tolerated than other treatments but, as up to 40% of patients did not respond to rituximab, alternative immunosuppressive therapies may still be required for a substantial minority of patients.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research